- iCo Therapeutics Inc. (ICO) announces shareholder approval of business combination with Satellos Bioscience Inc.
- Shares of the combined company are expected to begin trading on the TSX Venture Exchange as Satellos Bioscience Inc. under the symbol ‘MSCL’
- iCo is a Canadian biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat ocular and infectious diseases
- iCo generally focuses on in-licensing drug candidates with a clinical history and re-dose, reformulate and develop drug candidates
- iCo Therapeutics Inc. (ICO) is sitting at C$0.10 as of March 19
iCo Therapeutics Inc. (ICO) shareholders have approved iCo’s proposed business combination with Satellos Bioscience Inc.
Shares of the combined company are expected to begin trading on the TSX Venture Exchange as Satellos Bioscience Inc. under the symbol ‘MSCL’ during the week of August 9, 2021.
William Jarosz, the CEO of iCo commented on the transaction.
“The transaction was approved by 98.5 per cent of the shareholders voting at the annual and special meeting of the shareholders.
“The shareholders recognized the value that the Satellos assets bring to the combined business and the extraordinary opportunities they offer for the future. We are grateful for this support and will work diligently going forward to ensure that this support is warranted. We are very excited about what lies ahead for iCo’s shareholders.”
iCo is a Canadian biotechnology company focused on identifying, developing and commercializing drug candidates to treat ocular and infectious diseases.
iCo generally focuses on in-licensing drug candidates with a clinical history and re-dose, reformulate and develop drug candidates for the treatment of ocular and infectious diseases.
iCo currently has two in-licensed product candidates in various stages of development: iCo-008 (or for potential use in eotaxin-1 mediated indications, sub-licensed to Alexion Pharmaceuticals Inc., and an oral Amphotericin B delivery system under internal development for potential use in fungal infections).
iCo Therapeutics Inc. (ICO) is sitting at C$0.10 as of March 19.
